Appendix 7: Vaccine presentation, preparation, disposal, and needle-stick recommendations

Similar documents
Instructions for Use Enbrel (en-brel) (etanercept) for injection, for subcutaneous use Multiple-dose Vial

How to Use ENBREL : Vial Adapter Method

Standard operating procedures for preparation and administration of intramuscular injections. No Action Rationale

ALPROLIX Coagulation Factor IX (Recombinant), Fc Fusion Protein INSTRUCTIONS FOR USE Do not Do not YOUR KIT CONTAINS:

INSTRUCTIONS FOR PREPARING AND GIVING AN INJECTION OF ENBREL POWDER

Package Leaflet: Information for the User

Patient Information Publications Warren Grant Magnuson Clinical Center National Institutes of Health

The Enbrel SureClick autoinjector is a single-dose prefilled autoinjector. It contains one 50 mg dose of Enbrel.

Prothrombinex -HT Human prothrombin complex, freeze-dried.

MAKE SMART INJECTION CHOICES INJECTION PROVIDERS GUIDE FOR SAFE INJECTIONS

What Biostate is used for

1.0 Purpose The purpose of this guideline is to ensure the safe administration of intramuscular injections to Cheshire Ireland service users.

Instructions for Use HEMLIBRA (hem-lee-bruh) (emicizumab-kxwh) injection, for subcutaneous use

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

What employees should know about UNIVERSAL PRECAUTIONS. They re work practices that help prevent contact with blood and certain other body fluids.

IMPORTANT: PLEASE READ

INSTRUCTIONS FOR USE. Norditropin NordiFlex Somatropin (rdna origin) injection 30 mg/3 ml Prefilled Pen

HOW TO USE... 5mg. Pocket Guide

IMPORTANT: PLEASE READ

Instructions for Use Enbrel (en-brel) (etanercept) Single-use Prefilled SureClick Autoinjector

Human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF) complex, powder for injection. are essential for normal blood clotting.

Instructions For Use PRALUENT (PRAHL-u-ent) (alirocumab) Injection, for Subcutaneous Injection Single-Dose Pre-Filled Syringe (75 mg/ml)

BAYER: KOGENATE FS WITH BIOSET (Recombinant FVIII)

Instructions for Use. For use with. 10 mg vial

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

MYALEPT (MAI-uh-lept) (metreleptin) for injection for subcutaneous use

EVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11

Instructions for Use Enbrel (en-brel) (etanercept) injection, for subcutaneous use Single-dose Prefilled Syringe

The Enbrel SureClick autoinjector is a single-dose prefilled autoinjector. It contains one 50 mg dose of Enbrel.

Vial. A healthcare provider should show you how to inject MYALEPT before you use it for

Orion ISO Universal Precautions Employee Training Module

VACCINE MANAGEMENT. Recommendations for Handling and Storage of Selected Biologicals. January 2001 DEPARTMENT OF HEALTH AND HUMAN SERVICES

IMPORTANT: PLEASE READ. Don t

Instructions for Use. Welcome!

SUBJECT: Management of Human Body Fluids/Waste (Bloodborne Pathogens)

Pfizer, BeneFIX R2 Recombinant Factor IX

Education for self administration of intravenous therapy HOME IV THERAPY. 30 minute - Baxter Pump Tobramycin

Patient/Carer instructions for the administration of Subcutaneous Cytarabine

EVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3

Vaccine Administration. Olivia Trench, CNS (General Practice) The Mall Medical Centre, Tuam, Co Galway

MICAFUNGIN MIXING

INSTRUCTIONS FOR USE TYMLOS (tim lows ) (abaloparatide) injection, for subcutaneous use

Standard Precautions & Mercury Spill Management. Dr. Richa Mishra, Assistant Professor Dept, of Microbiology SGPGIMS, Lucknow

CIMZIA (certolizumab pegol)

HEPATITIS HEPATITIS A. The Hepatitis Alphabet HOW DOES ONE GET HEPATITIS A? THE SYMPTOMS of HEPATITIS A

Routine Immunization Procedures. Section 4. Newfoundland and Labrador Immunization Manual. Routine Immunization Procedures

SAFE Needle Disposal

Acknowledgement goes to WHO for use of their hand washing technique

Instructions for Use Neulasta (nu-las-tah) (pegfilgrastim) Injection, for subcutaneous use Single-Dose Prefilled Syringe. Plunger rod Used plunger rod

Blood Borne Pathogens (BBP)

Bloodborne Pathogens in the Workplace

Version Number: 1.4 Version Date: 27 April 2017 Next Review: April 2018

Infection Control. Chapter 11 Intro to HST

Universal Precautions

PART III: CONSUMER INFORMATION

A step-by-step preparation guide

Patient Education Pharmacy Services

ANTIBODY SCREENING by Uni-Gold Recombigen HIV

Sharps Container (not included) 1 Gather and check supplies. Gather supplies

H1N1 Vaccine Administration Manual for Paramedics

USER GUIDE. Melanotan must not be used if you are:

TOPIC 4 HANDLING HEALTH PROTECTION & SAFETY PRACTICES FOR MEDICAL STAFF & WASTE HANDLERS TRAINING & PUBLIC EDUCATION

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Viral or Suspected Viral Gastroenteritis Outbreaks

INSTRUCTIONS FOR USE HUMIRA 40 MG/0.8 ML, 20 MG/0.4 ML AND 10 MG/0.2 ML SINGLE-USE PREFILLED SYRINGE

AVIAN INFLUENZA COMMODITIES TRAINING GUIDE MODULE 3 - SAMPLING, RAPID TESTING AND PACKAGING PARTICIPANT HANDOUTS

Seasonal Influenza Peer Vaccination Programme Immunisation Process

VACCINE ADMINISTRATION CARMEL FINNERTY 30/11/2016

HUMULIN 70/30 KwikPen

BLOOD ALCOHOL LEGAL DRAW

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. Teduglutide for injection

Management of Exposure to Needlestick Injuries & Body Fluids

INSTRUCTIONS FOR USE. EMGALITY TM (em-gal-it-ē) (galcanezumab-gnlm)

Instructions for Use. HUMALOG KwikPen. insulin lispro injection (rdna origin) 100 units/ml, 3 ml pen

Chapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved.

CMC Annual Review of BLOODBORNE DISEASES. Prevention of Transmission for School Staff

CITY OF CHESTERFIELD POLICE DEPARTMENT GENERAL ORDER 7-02 EFFECTIVE: DECEMBER 1, 2002 CANCELS: GENERAL ORDER 94-7

A step-by-step preparation guide

Baxter, ADVATE Antihemophilic Factor (Recombinant)

INFORMATION FOR THE CONSUMER

Chapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved

Division 1 Introduction to Advanced Prehospital Care

Instructional Guide RECONSTITUTION OF IDELVION USING THE MIX2VIAL TRANSFER SET

HumaPen LUXURA HD INSULIN DELIVERY DEVICE INSTRUCTIONS FOR USE

Giving Medicine by Subcutaneous Injection

Chapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved.

SELF-INJECTION GUIDE

Before you use the TALTZ autoinjector, read and carefully follow all the step-by-step instructions.

CHEROKEE COUNTY SCHOOL DISTRICT

Cofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of

SymlinPen (SĬM-lĭnPen) 120 (pramlintide acetate) Pen-Injector

Infection Prevention and Control Induction Program. GRICG May 2015

Instructions for Use. BASAGLAR KwikPen. insulin glargine injection (100 units/ml, 3 ml pen)

Operational Guideline

Chapter 7, Medication Administration Part 1 Principles and Routes of Medication Administration Caution: Administering medications is business Always

Version Number: 1.4 Version Date: 27 April 2017 Next Review: April Laundry and hygiene facilities

PROCEDURE TITLE: BLOOD BORNE PATHOGENS EXPOSURE CONTROL PLAN PROCEDURE NO.: 5.21:1

May Safety Subject. Bloodborne Pathogens

LeadingAge Florida February 24, 2016

Bloodborne Pathogens. General

Transcription:

Appendix 7: Vaccine presentation, preparation, disposal, and needle-stick recommendations A7.1 Presentation of vaccines Most of the vaccines in current use are supplied in prefilled syringes or vials. The exceptions to this are the rotavirus vaccine, which is supplied as a syringe-style oral applicator, and the BCG vaccine, which is supplied as a multi-dose vial. A vial is a glass container with a rubber 33 seal on the top, protected by a metal or plastic cap until it is ready for use. Vials contain either liquid or powder (freeze-dried or pellet/cake) preparations. Vaccines should not be mixed in the same syringe, unless the manufacturer s data sheet specifically states it is permitted (eg, the DTaP-IPV-HepB vaccine is mixed with the Hib pellet for the Infanrixhexa vaccine). A7.2 Preparation and administration of vaccines In order to minimise the risk of spread of infection and needle-stick injury, vaccinators should observe standard occupational health and safety guidelines. Ensure proper hygiene is maintained (ie, regularly wash hands for at least 20 seconds and dry them for 20 seconds, or regularly use an alcohol-based hand rub if hands are not visibly soiled). Prepare the appropriate injection equipment for the vaccines to be administered (see section 2.2). Appendix 7: Vaccine presentation 33 Assume the rubber seal is latex unless stated latex-free. Immunisation Handbook 2017 657

Ensure the refrigerator temperature is within the required range of +2 C to +8 C before removing the vaccines (refer to the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017 34 ). Ensure the correct vaccine is taken from the refrigerator and that it is within the expiry date. Vaccines should only be drawn up after informed consent has been obtained and the vaccine requirements determined. This should include an NIR status query (if applicable) if there is uncertainty about previous doses. Any vaccines drawn up and not used should be discarded unless otherwise stated. Vaccines in vials require one needle to draw the vaccine into the syringe, and then a new needle to administer the vaccine. The passage of needles through rubber seals causes blunting, resulting in increased tissue trauma if that needle is used to administer the injection. Also, a new needle prevents tracking the vaccine through the skin and subcutaneous tissue, thereby reducing the risk of local reactions. Do not expel the air contained in the new needle it is sterile and minute in quantity (see chapter 2, Table 2.7). A7.2.1 Preparing vaccines supplied as a liquid preparation Where applicable, remove the detachable portion of the label from the vial or syringe and place it on (or with) the appropriate documentation. If there is no detachable label, note the batch number and expiry date. Inspect the vaccine for any foreign particulate matter and/or variation in the physical appearance described by the manufacturer if either is observed, do not use. Shake the vial: Most inactivated vaccines contain an adjuvant, and to obtain a uniform suspension they must be shaken vigorously prior to being drawn up. Flip the plastic cap off the vial, taking care not to touch the rubber seal. 34 Available at www.health.govt.nz/coldchain 658 Immunisation Handbook 2017

With the vial upright, insert the tip of the needle through the centre of the rubber seal, where it is thinner and easier to penetrate. Invert the vial and draw up the entire volume into the syringe. Withdraw the needle from the vial. Change the needle, choosing the appropriate gauge and length for administration. Administer the vaccine. Dispose of the empty vials, used syringes and needles into the sharps container. Complete the required documentation (eg, in the PMS). A7.2.2 Preparing vaccines supplied as powder/ pellet vaccines Some vaccines are presented as a prefilled syringe and freeze-dried (lyophilised) combination vaccines where: the pellet or powder preparation is reconstituted with the diluent (vial or prefilled syringe) supplied by the manufacturer (eg, MMR or Hib), or the pellet or powder preparation is reconstituted with a prefilled syringe containing vaccine (eg, DTaP-IPV-HepB/Hib). The method for reconstituting the vaccine varies depending upon whether vials or prefilled syringes are used, as follows. Reconstituting vaccines where the diluent is in a vial Where applicable, remove the detachable portion of the label from the diluent and/or vaccine (powder/pellet) vials and place these on (or with) the appropriate documentation. If there are no detachable labels, note the batch number and expiry date for both vaccine and diluent. Inspect the vaccine (powder/pellet) and diluent vials for any foreign particulate matter and/or variation in the physical appearance described by the manufacturer if either is observed, do not use. Flip the plastic cap off the diluent vial, taking care not to touch the rubber seal. Appendix 7: Vaccine presentation Immunisation Handbook 2017 659

With the diluent vial upright, insert the needle tip through the centre of the rubber seal, where it is thinner and easier to penetrate. Invert the vial and draw up the entire volume of diluent into the syringe. Flip the plastic cap off the powder/pellet vial, and slowly, to avoid frothing, empty the contents of the syringe (diluent) into the powder/pellet vial, using the vial entry technique mentioned above. Swirl the vial gently to dissolve the powder/pellet. The needle and syringe may be removed or left in place. After reconstitution the vaccine should be checked to see that the colour compares with the information supplied by the manufacturer on the data sheet and that there is no particulate matter present. If the colour does not match the manufacturer s information, do not use. Withdraw the entire volume of the reconstituted vaccine into the syringe. Withdraw the needle from the vial. Change the needle, choosing the appropriate gauge and length for administration. Once reconstituted, the vaccine must be used within the manufacturer s recommended period. See the respective vaccine data sheets for more information. Administer the vaccine. Dispose of the empty vials, used syringes and needles into the sharps container. Complete the required documentation (eg, in the PMS). Reconstituting vaccines where the vaccine or diluent is in a prefilled syringe Where applicable, remove the detachable portion of the label from the prefilled syringe and/or vaccine (powder/pellet) vial and place these on (or with) the appropriate documentation. If there are no detachable labels, note the batch number and expiry date for both the prefilled syringe and the vaccine (powder/pellet) vial. 660 Immunisation Handbook 2017

Inspect the prefilled syringe and vaccine (powder/pellet) vial for any foreign particulate matter and/or variation in the physical appearance described by the manufacturer if either is observed, do not use. Flip the plastic cap off the powder/pellet vial, and with the vial upright, insert the prefilled syringe needle tip through the centre of the rubber seal, where it is thinner and easier to penetrate. Slowly, to avoid frothing, empty the contents of the prefilled syringe into the vial. Swirl the vial gently to dissolve the powder/pellet. The needle and syringe may be removed or left in place. After reconstitution the vaccine should be checked to see that the colour compares with the information supplied by the manufacturer on the data sheet and that there is no particulate matter present. If the colour or presentation does not match the manufacturer s information, do not use. Withdraw the entire volume of the reconstituted vaccine into the syringe. Withdraw the needle from the vial. Change the needle, choosing the appropriate gauge and length for administration. Once reconstituted, the vaccine must be used within the manufacturer s recommended period. See the respective vaccine data sheets for more information. Administer the vaccine. Dispose of the empty vials, used syringes and needles into the sharps container. Complete the required documentation (eg, in the PMS). A7.2.3 Preparing vaccines supplied as prefilled syringes Where applicable, remove the detachable portion of the label from the prefilled syringe and place it on (or with) the appropriate documentation. If there is no detachable label, note the batch number and expiry date. Appendix 7: Vaccine presentation Immunisation Handbook 2017 661

Inspect the vaccine for any foreign particulate matter and/or variation in the physical appearance described by the manufacturer if either is observed, do not use. Shake the syringe: Most inactivated vaccines contain an adjuvant, and to obtain a uniform suspension they must be shaken vigorously prior to being drawn up. Do not expel air if the needle is fixed (eg, with an influenza vaccine). This prevents tracking the vaccine through the skin and subcutaneous tissue, thereby reducing the risk of local reactions. When the needle is not fixed, expel the air to the hub of the syringe and then attach an appropriate length needle. Administer the vaccine. Dispose of the used syringe and needle into the sharps container. Complete the required documentation (eg, in the PMS). A7.2.4 Preparing the rotavirus vaccine The rotavirus vaccine is administered orally. It is available as a syringetype applicator with a plunger stopper. Remove the detachable portion of the label (which includes the batch number but not the expiry date) and place it on (or with) the appropriate documentation. Note the expiry date. Inspect the vaccine for any foreign particulate matter and/or variation in the physical appearance described by the manufacturer if either is observed, do not use. Remove the protective tip cap from the oral applicator. Administer the entire contents of the oral applicator into the infant s mouth, towards the inner cheek. Discard the empty applicator and cap into the sharps container. For more information, refer to the manufacturer s data sheet (available on the Medsafe website, www.medsafe.govt.nz). 662 Immunisation Handbook 2017

A7.2.5 Preparing vaccines supplied as multi-dose vials 35 The vial should be marked with the date and time of opening and the vaccinator s initials. Shake the vial before use and before drawing up subsequent vaccine doses. Inspect the vaccine for any foreign particulate matter and/or variation in the physical appearance described by the manufacturer if either is observed, do not use. To ensure optimal vial dosage and minimal vaccine wastage, use a 1 ml syringe. Flip the plastic cap off the vial, taking care not to touch the rubber seal. Inspect the rubber seal. If there is any doubt about the integrity of the seal (eg, the vial leaks when turned upside down), do not use. Ideally, draw up all doses of the vaccine at the same time; this allows the drawing-up needle to remain in the vial and avoids the need for alcohol swabbing (of the rubber seal). Alcohol swabs should be used with caution. There is an increased risk of alcohol contamination when the swabbed rubber seal is repeatedly pierced. If an alcohol swab is used, allow 30 seconds for the alcohol to completely dry before inserting the needle into the rubber seal. Use each vial in one session of vaccinating and discard the vial four hours after first opening (or, follow the manufacturer s instructions), even if the vaccine has not been used. Appendix 7: Vaccine presentation 35 Sources: World Health Organization. 2014. WHO Policy Statement: Multidose Vial Policy (MDVP) Handling of multi-dose vaccine vials after opening. URL: http://apps.who.int/iris/bitstream/10665/135972/1/who_ivb_14.07_eng. pdf; the Australian Technical Advisory Group on Immunisation and the National Centre for Immunisation Research and Surveillance. Immunisation Handbook 2017 663

A7.3 Disposal of needles, syringes and vaccine vials Note: For information about returning vaccines for destruction (such as in the event of a cold chain excursion or failure), see the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017. 36 Do not separate needles from syringes or recap needles, unless a recapping device is used. All needles plus empty or partly used vials, syringes, dosing tubes and caps should be discarded into the sharps container for crush incineration. A7.3.1 Sharps containers Sharps containers should be made of rigid, leak- and puncture-proof material. They must be fitted with a carrying handle and have an opening that is wide enough to allow disposable materials to be dropped into the container with one hand while still preventing removal of the contents. Sharps containers should be situated out of children s reach and available in every area where vaccinations take place. Sharps containers should be filled only to the indicated line, then sealed and given to an approved hazardous waste disposal person for incineration (as per the Resource Management Act 1991). A7.3.2 Spillages In the event of blood or vaccine splashes on the skin, thoroughly wash the area under cold running water, then wash with soap and water or the hand wash that vaccinators have available. In the event of spills on work surfaces, put on gloves and treat the spill by wiping the area with a disposable pad soaked in 0.5 percent hypochlorite (household bleach diluted 1 to 9 parts water). Repeat with the hypochlorite solution and a fresh pad, then clean up with 36 Available at www.health.govt.nz/coldchain 664 Immunisation Handbook 2017

water or a commercial detergent. Alternatively, granular hypochlorite can be used for liquid spills, by applying sufficient granules to absorb the spilt fluid and then cleaning up after 10 minutes contact time. Carefully seal all contaminated material in an approved biohazard bag for incineration by an approved hazardous waste disposal person. Contaminated linen is adequately treated by a routine hot wash cycle (60 70 C) using an ordinary bleach concentration. A7.3.3 Recommendations following a needle-stick injury In the event of a needle-stick injury, follow the guidelines below. The vaccinator should stop what they are doing and attend to the injury. Wounds and skin sites should be washed with soap and water. There is no evidence that encouraging bleeding or applying antiseptic reduces the risk of infection, but these actions are not contraindicated. The injury should be immediately reported to the medical advisor or employer, who should consider what immediate action is advisable. When the needle-stick injury involves exposure to an individual s blood, serological testing of that source individual should be sought and undertaken as soon as possible. Blood should be withdrawn from the affected vaccinator within a few days after the injury and counselling arranged. Testing for hepatitis B, hepatitis C and HIV serology should be undertaken. Depending on the infection status of the individual and the immune status of the injured vaccinator, it may be appropriate to start anti- HIV medications within the next few hours or to administer HBIG within the next few days. The blood-borne viruses of main concern in needle-stick injuries are hepatitis B, hepatitis C and HIV. All vaccinators should be immunised against hepatitis B and their antibody status known. Currently in New Zealand most HIV-infected individuals (or their parents/guardians) are likely to know their status at the time of immunisation, so HIV testing in case of needle-stick injuries is not Appendix 7: Vaccine presentation Immunisation Handbook 2017 665

routinely advocated. If there is a possibility that the individual could be HIV infected, the informed consent of the individual/parent/ guardian is required before blood is drawn for testing. Blood-borne virus exposures after vaccination are rarely of high risk: because of the small needle size there is seldom visible blood, and there is a low risk of blood-borne viruses in the community. For more information, see also section 8.5.7 for serological testing guidelines for hepatitis B, the Starship Clinical Guidelines for Needlestick Injuries 37 (for needle-stick injuries from needles discarded in the community) or your local DHB guidelines (if available). 37 Available at https://www.starship.org.nz/for-health-professionals/starshipclinical-guidelines/n/needlestick-injuries/ 666 Immunisation Handbook 2017